Dopamine, oxidative stress and protein-quinone modifications in parkinsons and other neurodegenerative diseases
This time frame varies based on the GLP-1 RA used
GLP-1 injections help reduce hunger, slow stomach emptying, and control food intake, making them highly effective for patients struggling with obesity or those with metabolic conditions like type 2 diabetes
Normally, eating, especially calorie-dense or highly palatable food, triggers the release of dopamine, a neurotransmitter associated with reward and motivation
In 2025, the World Health Organization issued its first global guideline on using GLP-1 medicines for obesity, recognizing that these drugs can produce 15 to 25 percent weight loss on average and improve heart, kidney, and metabolic health when combined with lifestyle support